Two Anti-Inflammatory Compounds Shown to be Capable of Accelerating Recovery From COVID-19

Monoclonal antibody tested at University of São Paulo and experimental drug given to patients in Italy by University of Pennsylvania research group promoted rapid improvement of respiratory function in patients in severe condition. Courtesy of Daniel Mezes - HC

Two independent clinical studies – one by researchers at the Center for Cell-Based Therapy (CTC) in Ribeirão Preto, state of São Paulo (Brazil), on the monoclonal antibody eculizumab, and the other by scientists at the University of Pennsylvania in Philadelphia (USA) on an experimental drug called AMY-101 – observed a significant anti-inflammatory effect that contributed to a faster recovery by severe COVID-19 patients. The results of the two studies, which set out to compare the compounds’ therapeutic potential, are reported in an article published in Clinical Immunology.

The two medications were administered separately. The monoclonal antibody, routinely used to treat blood diseases, was tested on patients at the teaching hospital (“Hospital das Clínicas”) run by the University of São Paulo’s Ribeirão Preto Medical School (FMRP-USP). AMY-101, a candidate drug developed by US-based pharmaceutical company Amynda, was given to patients at a hospital in Milan, Italy. Both produced promising results, but because AMY-101 is cheaper and performed better in the clinical trial, the two research groups envisage testing it on a larger number of patients in Brazil.

“Both compounds caused a robust anti-inflammatory response that culminated in a fairly rapid recovery of respiratory function in the patients,” says Rodrigo Calado, who led the study at FMRP-USP. Calado is affiliated with CTC, a Research, Innovation and Dissemination Center (RIDC) funded by FAPESP and based at FMRP-USP’s blood center.

The researchers concluded that the therapeutic benefits of eculizumab and AMY-101 were due to inhibition of a bloodstream cascade of proteins involved in immune response and known as the complement system.

Persistent dysregulated complement activation triggers the exacerbated inflammatory response to SARS-CoV-2 infection characterized by a systemic increase in pro-inflammatory cytokines and often referred to as a “cytokine storm”.

Unable to prevent infection of cells by the virus, the complement system enters a spiral of runaway continuous activation that leads to massive infiltration of monocytes and neutrophils into the infected tissues. This process can result in inflammatory damage to the walls of blood vessels surrounding vital organs, as well as disseminated microvascular injury and thrombosis, potentially culminating in multiple organ failure.

“Previous studies had shown the use of complement inhibitors to be a promising therapeutic strategy to ameliorate thrombo-inflammation in COVID-19 patients, and there were reports of cases with positive results,” Calado said. “However, as yet no one had elucidated the action or evaluated the efficacy of drugs already in use to treat diseases caused by complement alterations, such as eculizumab, or candidate drugs with this function such as AMY-101.”

To fill the gap the researchers conducted two clinical studies in which they compared the biological efficacy of eculizumab with that of the synthetic peptide AMY-101 in independent small groups of severe COVID-19 patients.

Ten patients aged between 18 and 80 were undergoing treatment at FMRP-USP’s Hospital das Clínicas. Once a week while hospitalized, they were given 900 mg of eculizumab, which inhibits the complement protein C5. Three patients hospitalized in Milan, Italy, were given 5 mg of AMY-101, developed to inhibit complement protein C3, also once a week. These two proteins perform the most important activities in the complement system.

The patients’ clinical responses showed that eculizumab and AMY-101 elicited a robust anti-inflammatory process, a sharp fall in levels of C reactive protein (CRP) and interleukin-6 (IL-6), and a marked improvement in lung function.

Inhibition of C3 by AMY-101 afforded broader therapeutic control, stronger lymphocyte recovery, a pronounced decline in neutrophil count, and more robust attenuation of the thrombo-inflammation induced by the exacerbated response to viral infection.

“The results of the clinical trials showed that inhibiting components of the complement system sharply reduces inflammation,” Calado said.

In light of the promising results of the two clinical trials, the CTC and UPenn researchers now plan to conduct a Phase 3 trial with more than 100 severe COVID-19 patients, who will be given only AMY-101 in an effort to assess the drug’s efficacy on a wider scale.

The study will be conducted at FMRP-USP’s Hospital das Clínicas, and will probably involve other research institutions in Brazil. “One of the advantages of AMY-101 is its low cost. It’s much less expensive than eculizumab,” Calado said.

Source: São Paulo Research Foundation (FAPESP)

 

4 Comments on "Two Anti-Inflammatory Compounds Shown to be Capable of Accelerating Recovery From COVID-19"

  1. 502649 463369Nice to be visiting your weblog once much more, it continues to be months for me. Nicely this post that ive been waited for so lengthy. I want this write-up to total my assignment within the university, and it has same subject together along with your post. Thanks, terrific share. 48047

  2. 57189 177799A weblog like yours need to be earning a lot money from adsense.~::- 479126

  3. 867314 512941I discovered your weblog internet site on google and check some of your early posts. Continue to keep up the extremely very good operate. I just additional up your RSS feed to my MSN News Reader. Seeking forward to reading much more from you later on! 114666

  4. 932131 584052We clean up on completion. This could sound obvious but not many a plumber in Sydney does. We wear uniforms and always treat your home or office with respect. 900841

Leave a comment

Your email address will not be published.


*